{"transactions":[{"id":3296219,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2020-01-31T21:05:20.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":300000,"derivative":{"exercise_price":3.3,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-20-002418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924320002418/doc4.xml","form_type":"4"}},{"id":3299812,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2020-01-28T21:05:20.000Z","date":"2020-01-26","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units are fully vested and do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units are fully vested and do not have an expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-20-002210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/doc4.xml","form_type":"4"}},{"id":3299811,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"COMMON STOCK","published_at":"2020-01-28T21:05:20.000Z","date":"2020-01-26","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":105250,"source":{"system":"sec-edgar","filing":"0000899243-20-002210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/doc4.xml","form_type":"4"}},{"id":3683398,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2019-01-29T23:51:28.000Z","date":"2019-01-26","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020."}],"balance_after":12500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-19-002137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/doc4.xml","form_type":"4"}},{"id":3683397,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2019-01-29T23:51:28.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest as to 25% of the shares on January 25, 2020.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":60000,"derivative":{"exercise_price":6.01,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-19-002137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/doc4.xml","form_type":"4"}},{"id":3683396,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"COMMON STOCK","published_at":"2019-01-29T23:51:28.000Z","date":"2019-01-26","kind":"exercise","acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":92750,"source":{"system":"sec-edgar","filing":"0000899243-19-002137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/doc4.xml","form_type":"4"}},{"id":3724280,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2018-12-19T21:11:41.000Z","date":"2018-12-19","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units have vested and settled as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These restricted stock units have vested and settled as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-18-031411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/doc4.xml","form_type":"4"}},{"id":3724279,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"COMMON STOCK","published_at":"2018-12-19T21:11:41.000Z","date":"2018-12-19","kind":"exercise","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit represents right to receive one share of Issuer common stock."}],"balance_after":85250,"source":{"system":"sec-edgar","filing":"0000899243-18-031411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/doc4.xml","form_type":"4"}},{"id":3724278,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"COMMON STOCK","published_at":"2018-12-19T21:11:41.000Z","date":"2018-12-17","kind":"sale","acquired":false,"shares":14282,"price":6.3936,"value":91313.3952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $6.2100 to $6.5900.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":75250,"source":{"system":"sec-edgar","filing":"0000899243-18-031411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/doc4.xml","form_type":"4"}},{"id":3758413,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-11-19T21:27:52.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":14279,"price":8.2577,"value":117911.6983,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $8.0600 to $8.4200.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":89532,"source":{"system":"sec-edgar","filing":"0000899243-18-029310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318029310/doc4.xml","form_type":"4"}},{"id":3789636,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-10-16T20:16:37.000Z","date":"2018-10-15","kind":"sale","acquired":false,"shares":14279,"price":5.9388,"value":84800.1252,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $5.6400 to $6.2912.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":103811,"source":{"system":"sec-edgar","filing":"0000899243-18-026790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318026790/doc4.xml","form_type":"4"}},{"id":3811371,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-09-20T01:22:25.000Z","date":"2018-09-17","kind":"sale","acquired":false,"shares":14279,"price":7.2747,"value":103875.4413,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $7.0914 to $7.5600.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":118090,"source":{"system":"sec-edgar","filing":"0000899243-18-024819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/doc4.xml","form_type":"4"}},{"id":3811370,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-09-20T01:22:25.000Z","date":"2018-08-15","kind":"sale","acquired":false,"shares":14279,"price":7.5684,"value":108069.1836,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $7.2500 to $7.7600.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This filing is being reported late due to an inadvertent administrative error."}],"balance_after":132369,"source":{"system":"sec-edgar","filing":"0000899243-18-024819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/doc4.xml","form_type":"4"}},{"id":3811369,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-09-20T01:22:25.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":14279,"price":8.0818,"value":115400.0222,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $7.8800 to $8.1400.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.  This filing is being reported late due to an inadvertent administrative error."}],"balance_after":146648,"source":{"system":"sec-edgar","filing":"0000899243-18-024819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/doc4.xml","form_type":"4"}},{"id":3865005,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"COMMON STOCK","published_at":"2018-07-18T20:58:39.000Z","date":"2018-07-15","kind":"sale","acquired":false,"shares":14279,"price":8.1046,"value":115725.5834,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $7.82 to $8.60.  The Reporting Persons undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":160927,"source":{"system":"sec-edgar","filing":"0000899243-18-020074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318020074/doc4.xml","form_type":"4"}},{"id":3887884,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2018-06-19T21:03:48.000Z","date":"2018-06-19","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units have vested and settled or will vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units have vested and settled or will vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018."}],"balance_after":10000,"derivative":{"underlying":"COMMON STOCK","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-18-017198","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318017198/doc4.xml","form_type":"4"}},{"id":3887883,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"COMMON STOCK","published_at":"2018-06-19T21:03:48.000Z","date":"2018-06-19","kind":"exercise","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":175206,"source":{"system":"sec-edgar","filing":"0000899243-18-017198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318017198/doc4.xml","form_type":"4"}},{"id":3890277,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Common Stock","published_at":"2018-06-18T20:43:51.000Z","date":"2018-06-15","kind":"sale","acquired":false,"shares":14279,"price":8.5668,"value":122325.3372,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $8.39 to $8.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":170206,"source":{"system":"sec-edgar","filing":"0000899243-18-017017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318017017/doc4.xml","form_type":"4"}},{"id":3955845,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Common Stock","published_at":"2018-04-26T20:55:53.000Z","date":"2018-04-25","kind":"sale","acquired":false,"shares":14279,"price":7.5822,"value":108266.2338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.47 to $7.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":184485,"source":{"system":"sec-edgar","filing":"0000899243-18-010837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318010837/doc4.xml","form_type":"4"}},{"id":4084587,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-01-31T02:01:52.000Z","date":"2018-01-30","kind":"grant","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option will vest as to 25% of the shares on January 30, 2019.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":10.42,"expiration_date":"2028-01-29","underlying":"COMMON STOCK","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-18-002334","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318002334/doc4.xml","form_type":"4"}},{"id":4084586,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2018-01-31T02:01:52.000Z","date":"2018-01-26","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020."}],"balance_after":20000,"derivative":{"underlying":"COMMON STOCK","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-18-002334","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318002334/doc4.xml","form_type":"4"}},{"id":4084585,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-01-31T02:01:52.000Z","date":"2018-01-26","kind":"sale","acquired":false,"shares":1738,"price":11.02,"value":19152.76,"ownership":{"direct":true},"balance_after":198764,"source":{"system":"sec-edgar","filing":"0000899243-18-002334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318002334/doc4.xml","form_type":"4"}},{"id":4084584,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-01-31T02:01:52.000Z","date":"2018-01-26","kind":"exercise","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":200502,"source":{"system":"sec-edgar","filing":"0000899243-18-002334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318002334/doc4.xml","form_type":"4"}},{"id":4084575,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-01-31T01:54:43.000Z","date":"2017-12-19","kind":"sale","acquired":false,"shares":1623,"price":10.14,"value":16457.22,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Due to a clerical error, the reporting person's original Form 4 filed on December 20, 2017 set forth an incorrect amount of common stock beneficially owned by the reporting person following the reported transaction.  This Form 4/A corrects the error and presents the correct number of common stock beneficially owned by the reporting person following the reported transaction."}],"balance_after":195502,"source":{"system":"sec-edgar","filing":"0000899243-18-002323","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318002323/doc4a.xml","form_type":"4/A","original_submission_date":"2017-12-20"}},{"id":4084574,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-01-31T01:54:43.000Z","date":"2017-12-19","kind":"exercise","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Due to a clerical error, the reporting person's original Form 4 filed on December 20, 2017 set forth an incorrect amount of common stock beneficially owned by the reporting person following the reported transaction.  This Form 4/A corrects the error and presents the correct number of common stock beneficially owned by the reporting person following the reported transaction."}],"balance_after":197125,"source":{"system":"sec-edgar","filing":"0000899243-18-002323","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318002323/doc4a.xml","form_type":"4/A","original_submission_date":"2017-12-20"}},{"id":4124719,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Restricted Stock Units","published_at":"2017-12-20T21:56:45.000Z","date":"2017-12-19","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-17-029325","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317029325/doc4.xml","form_type":"4"}},{"id":4124718,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Common Stock","published_at":"2017-12-20T21:56:45.000Z","date":"2017-12-19","kind":"sale","acquired":false,"shares":1623,"price":10.14,"value":16457.22,"ownership":{"direct":true},"balance_after":59437,"source":{"system":"sec-edgar","filing":"0000899243-17-029325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317029325/doc4.xml","form_type":"4"}},{"id":4124717,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Common Stock","published_at":"2017-12-20T21:56:45.000Z","date":"2017-12-19","kind":"exercise","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":61060,"source":{"system":"sec-edgar","filing":"0000899243-17-029325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317029325/doc4.xml","form_type":"4"}},{"id":4275062,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Restricted Stock Units","published_at":"2017-06-21T21:24:22.000Z","date":"2017-06-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017; 25% on June 19, 2018; and 50% on December 19, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017; 25% on June 19, 2018; and 50% on December 19, 2018."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-016868","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317016868/doc4.xml","form_type":"4"}},{"id":4478865,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Restricted Stock Units","published_at":"2017-01-27T22:56:32.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-17-002128","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317002128/doc4.xml","form_type":"4"}},{"id":4478864,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-27T22:56:32.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on January 26, 2018.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":50000,"derivative":{"exercise_price":9.89,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-17-002128","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317002128/doc4.xml","form_type":"4"}},{"id":4598680,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":152081,"kind":"person","name":"Aunins John G.","position":1,"cik":"0001643756","reported_name":"Aunins John G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer & EVP"}}],"security":"Stock Option (right to buy)","published_at":"2016-09-20T20:59:39.000Z","date":"2016-09-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on September 19, 2017. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":30000,"derivative":{"exercise_price":12.55,"expiration_date":"2026-09-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-16-029446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924316029446/doc4.xml","form_type":"4"}}]}